Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 2 | Rare Historical Photos

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

MarketBeat

Is Archer Aviation Stock a Buy, Sell, or Hold on Trump’s Flying Car Executive Order?

Archer Aviation shares rallied on Trump’s executive order in favor of eVTOL technology. HC Wainwright sees significant further upside in ACHR stock.

Barchart

Analysts Say MicroStrategy Is a ‘Turbocharger.’ Should You Buy MSTR Stock Here?

MSTR shares are trading at a discount to consensus price targets in May 2025.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Plug Power Is Surging on New Financing. Should You Buy the Penny Stock Here?

Plug Power announced strong Q1 preliminary results, operational improvements, and a new credit agreement on Monday. But is that reason enough to buy PLUG shares?

Barchart

Analyst Upgrade Shows Over Double Bagger Potential for BigBear.ai

BigBear.ai recently received a massive price target increase from one Wall Street analyst. Is it time to get in on this small AI stock?

MarketBeat

2 Penny Stocks That Wall Street Believes Can Soar Around 292% to 442%

Analysts believe these two penny stocks have outstanding long-term potential.

Barchart

Mizuho Analyst Remains Bullish On The EV Sector; Finds Rivian Better Positioned

Mizuho analyst Vijay Rakesh reiterated his Buy ratings on Rivian Automotive, Inc (NASDAQ:RIVN) and the $65 price target. He saw RIVN as a pure play and a strong early mover in the EV market, focusing on the higher-growth SUV and light truck market and a robust commercial vehicle roadmap beginning with Amazon.Com, Inc. (NASDAQ:AMZN). Rivian is…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging

Ayala Pharmaceuticals Inc (NASDAQ:AYALA) reported data from Part A of its Phase 2 (RINGSIDE) trial evaluating AL102 in patients with desmoid tumors on Tuesday. At 16 weeks, one of 13 patients treated with AL102 demonstrated an unconfirmed partial response, which HC Wainwright believes signals encouraging initial activity. HC Wainwright reiterated the Buy rating on the…

Benzinga

HC Wainwright Finds 'Synergies In Treatment' For This Bipolar-Focused Stock

HC Wainwright initiated coverage on NRx Pharmaceuticals Inc (NASDAQ:NRXP) with a Buying rating and a price target of $2. Earlier today, the FDA declined to issue an Emergency Use Authorization for NRx's Zyesami for a subgroup of patients who also received Gilead Sciences Inc's (NASDAQ:GILD) remdesivir in addition to Zyesami. The analyst is bullish on: Significant potential for NRX-101 for…

Benzinga

HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock

HC Wainwright has initiated Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22 (310% upside). The analysts see gastrointestinal stromal tumors (GISTs) treatment space reigniting with the entrance of a Theseus' pan-KIT inhibitor THE-630, with a high likelihood of 5L approval with earlier line potential. The analysts believe THE-630 can…

Benzinga

Analysts Still Believe Verrica's Ycanth Is Approvable Despite FDA Response Letter

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) held a Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of Ycanth (VP-102) for molluscum contagiosum. HC Wainwright says VP-102 was approvable, and at the time of the Complete Response Letter (CRL), Verrica had already engaged a potential alternate solution supplier. It reiterates…

Benzinga

Why Did HC Wainwright Downgrade Addex Therapeutics

Last week, Addex Therapeutics Ltd (NASDAQ:ADXN) terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow rate of patient recruitment. Addex is suspending its financial guidance. Hence HC Wainwright downgraded its rating to Neutral from Buy without a price target, as dipraglurant…

Benzinga

HC Wainwright Believes This Cancer-Focused Stock Is Undervalued At $550M

HC Wainwright initiated coverage of Celularity Inc (NASDAQ:CELU) with a Buy rating and a price target of $15. HC Wainwright believes Celularity's current valuation of approximately $550 million is undervalued considering the upside potential of the company's platform and provides an attractive entry point for long-term investors. The analyst wrote that the company had…

Benzinga

HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate

HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock

Olumiant (baricitinib), a Janus kinase (JAK) inhibitor, was developed by Incyte Corp (NASDAQ:INCY) and launched in collaboration with Eli Lilly And Co (NYSE:LLY), received FDA approval for hair loss disorder known as alopecia areata (AA). Olumiant was first approved for the treatment of rheumatoid arthritis (RA) in 2018. The above nod is expected to…

Benzinga

Read Why Forma Therapeutics' Current Price Level Is 'Attractive Entry Point'

During the European Hematology Association (EHA) conference, Forma Therapeutics Holdings Inc (NASDAQ:FMTX) presented updated results from the 12-week open-label extension (OLE) of etavopivat's Phase 1 trial in sickle cell disease. Treatment with etavopivat 400mg QD elicited a >1g/dL hemoglobin (Hb) increase in 73% of the 15 patients and an average maximal Hb increase of…

Benzinga

HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications

ADC Therapeutics SA (NYSE:ADCT) presented updated efficacy and safety results from the Phase 2 trial of camidanlumab tesirine (Cami, formerly ADCT-301) in relapsed or refractory Hodgkin lymphoma. Cami demonstrated a 70.1% overall response rate (ORR), with a 33.3% complete response (CR) rate. From a safety perspective, eight of 117 patients developed Guillain-Barré syndrome…

Benzinga

Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability

Caribou Biosciences Inc (NASDAQ:CRBU) announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Following a single dose at the initial dose level of 40 million CAR-T cells, a 100% complete response (CR) rate (6 of 6…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

HC Wainwright Sees This Small-Cap Biotech As Undervalued, Underappreciated

At the European Hematology Association (EHA) meeting, Oncternal Therapeutics Inc (NASDAQ:ONCT) presented initial preclinical results of Oncternal's ROR1 CAR containing the antigen-binding region of zilovertamab. The data showed that The ROR1 CAR mediated target recognition and cell activation when expressed in either T cells or NK cells. Also, ROR1 CAR-T cells demonstrated dose-dependent anti-tumor…

Benzinga

SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch

HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week.

Benzinga

HC Wainwright Says Non-mRNA COVID-19 Option Underappreciated

HC Wainwright says safety concerns were noted for Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine, but the strength of data showed that benefit outweighs risks.

Benzinga

HC Wainwright Says Viaskin Benefit Affirmed In Toddlers...What's Next?

HC Wainwright believes the most significant takeaway from DBV Technologies SA's (NASDAQ:DBVT) trial update was that 250ug treatment achieved the primary endpoint of difference between the percentage of treatment responders in the active compared to the placebo arm after 12 months. It reiterates a Buy rating and a $10 price target. Moreover, the analysts highlight that the…

Benzinga

Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics

Late last week, Atara Biotherapeutics Inc (NASDAQ:ATRA) announced that Bayer AG (OTC:BAYRY) intends to terminate the exclusive worldwide licensing agreement for Atara's mesothelin-targeted allogeneic and autologous CAR-T assets, ATA3271 and ATA2271. The enrollment was paused in the Phase 1 trial of ATA2271 for mesothelioma after a patient death. The move followed a strategic review and asset-level prioritization.…

StockNews.com

1 Biotech Stock to Buy and 1 to Sell

Increasing investments in R&D to develop new therapies, rising cases of chronic diseases, and an aging population should drive the biotech market’s growth. Therefore, we think it could be wise to invest in the shares of fundamentally sound biotech company Vertex Pharmaceuticals (VRTX). Conversely, we think the shares of Galmed…

Benzinga

Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock

U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.